Permar, Sallie Robey
(919) 684-2515
sallie.permar@duke.edu
103020, 2 Genome Ct MSRBII
Durham, NC 27710
Duke Human Vaccine Institute, Box 103020 MSRBII Rm 3072A
Durham, NC 27710

Webpages

Courses

IMMUNOL 494: Research Independent Study
GLHLTH 393: Research Independent Study in Global Health
PHARM 494: Research Independent Study
IMMUNOL 493: Research Independent Study
PHARM 493: Research Independent Study

Sallie Robey Permar

Wilburt C. Davison Distinguished Professor
Adjunct Professor in the Department of Pediatrics
Adjunct Professor in the Department of Pediatrics
Adjunct Professor in the Department of Pathology
Professor of Pediatrics
Associate Dean for Physician-Scientist Development
Adjunct Professor in the Department of Pathology
Professor of Pathology
Professor in Immunology
Professor in Immunology

Pages

Dr. Permar's work focuses on the development of vaccines to prevent vertical transmission of neonatal viral pathogens. She has utilized the nonhuman primate model of HIV/AIDS to characterize the virus-specific immune responses and virus evolution in breast milk and develop a maternal vaccine regimen for protection against breast milk transmission of HIV. In addition, Dr. Permar's lab has advanced the understanding of HIV-specific immune responses and virus evolution in vertically-transmitting and nontransmitting HIV-infected women, defining maternal immune responses that may protect against neonatal transmission of HIV. Importantly, Dr. Permar has established a nonhuman primate model of congenital CMV infection adn is using this model to establish the maternal immune responses that are necessary for protection against placental virus transmission. Finally, Dr. Permar is studying the impact and prevention of postnatal CMV transmission in preterm infants.

Research Areas

Education

  • Other, Children's Hospital Boston (2009)
  • Other, Children's Hospital Boston (2007)
  • Ph.D., Johns Hopkins University (2004)
  • M.D., Harvard Medical School (2004)

Publications

What are the key pediatric public policy priorities as the COVID-19 pandemic persists? (05/2023)
Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates. (04/2023)
Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV. (04/2023)
Does congenital cytomegalovirus infection contribute to the development of acute lymphoblastic leukemia in children? (04/2023)
Human Cytomegalovirus Infection Primes Fetal Natural Killer Cells for Fc-Mediated Antiviral Defense. (03/2023)
Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV. (03/2023)
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. (03/2023)
A simple model for viral decay dynamics and the distribution of infected cell life spans in SHIV-infected infant rhesus macaques. (02/2023)
Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. (01/2023)
A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus. (01/2023)

Mailing Address

Nicholas Institute for Energy, Environment & Sustainability
Box 90467
Durham, NC 27708

Street / Delivery Address

Nicholas Institute for Energy, Environment & Sustainability
140 Science Drive
Gross Hall, Suite 101
Durham, NC 27708

919-613-1305